The Adoption Paradox
Why Diagnostic Innovation Is Accelerating while Clinical Integration Is Slowing.

After 25 years in the IVD industry, having entered the space in 2002, I have observed a fundamental shift in the commercialization window. This briefing explores why technical validation is no longer the primary hurdle for diagnostic adoption.

The real challenge is structural: the gap between FDA clearance and sustainable clinical revenue. We call this The Adoption Paradox.

Most diagnostic companies believe that FDA clearance is the hardest milestone.

It is not.

The real challenge begins after clearance, when companies attempt to convert clinical validation into real-world adoption. This is where most diagnostics stall: not because the science is wrong, but because the commercial architecture was never built.

This gap is what we define as the commercialization window.

Diagnostic founders, investors, and even experienced operators often anchor on a flawed assumption:

Strong clinical performance will naturally lead to market adoption.

In reality, adoption in diagnostics is not driven by performance alone. It is driven by alignment across multiple systems:

• Clinical workflow integration
• Reimbursement and payer coverage architecture
• Economic value to the provider
• Channel access and distribution infrastructure
• Physician behavior and guideline integration

If these are not intentionally designed, even the most clinically accurate test will struggle to gain traction.

Evidence Designed for Regulators, Not Buyers

Most clinical studies are designed to achieve clearance, not adoption.

They demonstrate analytical performance and clinical validity, but fail to answer the questions that matter to:

• Payers: Does this reduce cost or improve outcomes
• Providers: Does this change how I treat patients
• Health systems: Does this improve throughput or reduce burden

Without clinical utility and economic evidence, adoption stalls.

Reimbursement Infrastructure Gaps

Many companies treat reimbursement as a post-clearance activity.

This is one of the most common and most costly structural failures.

Without a clear plan for coding, coverage, and payment, providers are left with uncertainty. Uncertainty kills utilization.

Placement Strategy Ambiguity

Where does the test live?

• Central lab
• Hospital lab
• Point of care
• Decentralized or home

Each setting has different buyers, economics, and workflow constraints.

Without a clear placement decision, strategy becomes diluted and ineffective.

Commercial Infrastructure Deficits

Distribution is not logistics. It is market access.

Without alignment at the distributor and field level, products fail to reach the right accounts or generate consistent utilization.

Pilot Programs Without Scale Architecture

Pilot programs create early traction, but they are not designed for scale.

Without standardized workflows, reimbursement clarity, and a repeatable sales motion, pilots remain isolated successes.

FDA clearance proves one thing: the test works. It demonstrates analytical validity and, in many cases, clinical validity. But clearance does not answer the questions that drive adoption.

Payers do not reimburse tests because they are accurate. They reimburse tests that change clinical decisions and improve patient outcomes. This distinction between validity (does the test measure what it claims?) and utility (does the test change what clinicians do?) is the single most misunderstood dynamic in diagnostic commercialization.

Without clinical utility evidence, payer coverage decisions stall. Without coverage, providers absorb financial risk. Without financial clarity, utilization collapses.

Even when the evidence is strong and reimbursement is secured, adoption can fail at the point of care. This is the physician workflow challenge: the physical and digital "last mile" of diagnostic integration.

A 15-minute patient encounter leaves no room for ambiguity. If the result does not flow seamlessly into the EMR, if the ordering process adds friction, if the turnaround time does not align with the clinical decision window, physicians will default to existing behavior.

Adoption infrastructure must account for how the test is ordered, how the result is delivered, how it integrates into existing clinical workflows, and how it fits into the rhythm of care delivery. This is not a technology problem. It is a design problem.

Companies that treat workflow integration as a post-launch optimization consistently underestimate the resistance they will encounter. The diagnostic that is easiest to use will win, not the one that is most analytically precise.

The Cost of Delayed Commercial Architecture

The most expensive mistake in diagnostic commercialization is not a failed study or a rejected submission. It is the 18 to 24 months of post-clearance stagnation that occurs when commercial architecture is treated as a post-regulatory activity.

When regulatory, clinical, and payer teams operate in sequence rather than in parallel, critical dependencies are missed. Evidence gaps are discovered after clearance. Reimbursement strategy begins without the data payers require. Channel partnerships are formed without clear economic models. The result is what we call the post-clearance plateau: a period of high burn and low utilization that erodes investor confidence and market position.

Early alignment between these teams is the defining characteristic of companies that achieve sustainable adoption. This is the AdvisoryDx approach: designing commercial architecture alongside clinical and regulatory development, not after it.

Companies that sequence market entry strategically compress time-to-revenue, reduce capital requirements, and build defensible market positions before competitors reach the same clinical endpoints.

These breakdowns are not random. They are systemic.

Diagnostic companies are built to solve for science, engineering, and regulatory approval.

But adoption requires a different system entirely.

It requires commercial architecture.

This includes:

• Evidence strategy aligned to payer and provider decision-making
• A defined reimbursement pathway before launch
• Clear care setting and placement design
• Channel strategy that drives utilization
• Commercial operating infrastructure that supports scale

Without this architecture, companies enter the market unprepared for adoption.

Between validation and adoption sits a critical phase:

The commercialization window.

This is where companies must translate:

• Clinical data into clinical utility
• Product capability into economic value
• Market access into actual utilization

Most companies underestimate this phase.

Some skip it entirely.

That is why so many diagnostics reach the market but fail to scale.

The companies that succeed design for adoption before they launch.

They:

• Build reimbursement strategy alongside clinical development
• Align studies with payer and guideline expectations
• Define where and how the test will be used
• Engage channel partners early
• Build a repeatable commercial model

They treat commercialization as a system, not a phase.

Since entering the IVD space in 2002, we have observed a fundamental shift in how diagnostic markets form and how adoption actually occurs.

In the early 2000s, diagnostics operated in a product-first paradigm. A strong assay, a clear clinical need, and a capable sales team were often sufficient to build a commercial business. Reimbursement was simpler. Payer scrutiny was lower. The path from clearance to revenue was shorter and more forgiving.

That paradigm no longer exists.

Today, the commercialization window demands an evidence-first architecture. Payers require clinical utility data before coverage decisions. Health systems require economic justification before formulary access. Physicians require workflow integration before behavior change.

The companies that recognize this shift early, and design for it, are the ones that achieve sustainable adoption. The companies that operate under the old paradigm, building a product and expecting the market to follow, are the ones that stall.

The commercialization window has not closed. It has become architectural.